ASCO 2026: key readouts in lung cancer – Clinical Trials Arena
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. CancerResearchMental HealthSafetyAnxietyNeurologyDosing Clinical Summary # Clinical Summary This commentary highlights a…
ASCO26: BMS and J&J debut shining multiple myeloma data – Clinical Trials Arena
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. CancerResearchIndustryMental HealthSafetyPolicyNeurology Why This Matters This article highlights the need for rigorous…
Lesser-known cannabis compounds show promise for treating alcohol addiction in rats
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchMental HealthNeurologyCBNTHCVAddictionAlcohol Why This Matters Clinicians treating patients with alcohol use…
Cannabis compounds reduce alcohol consumption in rats, study shows – leafie
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchTHCTHCVAlcoholNeurologyMental HealthSafety Why This Matters This preclinical finding suggests cannabinoid…
Cannabis Startup Leverages High Search Interest in Sour Diesel and THCV for Explosive Growth
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. THCIndustryResearchSafetyMental HealthHempCBD Why This Matters I need to note that this article appears to be…
SC legislators’ effort to restrict THC hemp products depends on Congress
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempTHCSafetyPediatricsResearchIndustry Clinical Summary South Carolina legislators are attempting to restrict the…
Patient First Coalition Supports DEA’s Medical Cannabis Review Process
The DEA medical cannabis review process is a pivotal step toward rescheduling cannabis to Schedule III. This change could expand clinical research opportunities and improve patient access to standardized cannabis therapies. The Patient First Coalition…
Louisiana Lawmakers Pass Bill To Create Psychedelic Therapy Pilot Program
Louisiana's psychedelic therapy pilot program legitimizes clinical research into psilocybin, ibogaine, and MDMA as potential treatments for conditions where conventional therapies have failed. This program may expand therapeutic options for patients with…
Hair Shedding, Weight Loss, and GLP-1 Therapy: Separating Signal from Speculation
GLP-1 hair loss risk has become a growing concern as semaglutide and tirzepatide use expands. A large propensity-matched cohort study found significantly higher rates of nonscarring hair loss among users of both medications compared with metformin. The…
In the Mix: 13 More Articles — May 30, 2026
This article reviews consumer preference cannabis terpene profiles and their impact on patient experiences. Understanding terpene profiles is key for clinicians interpreting patient reports. The focus on cannabis aroma offers insights into clinical…